Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-02-03
1998-02-24
Krass, Frederick
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 17, 514 18, 530317, 530329, 530330, 435 712, 435118, 435120, 435863, 435864, 435865, 435866, 540524, 540526, A61K 3812
Patent
active
057212090
ABSTRACT:
Exochelins can be used to prevent damage to living tissue from the formation or presence of the (.cndot.OH) radical. In particular, the invention is directed to the administration of exochelins to infarcted myocardium prior to or coincidental with reperfusion to prevent damage to myocardium from iron mediated free radical formation. Also presented is the chemical structure of exochelins and modified exochelins as well as other applications of these materials in the treatment and diagnosis of disease in mammals.
REFERENCES:
Chemical Abstracts 108:218746, "Mycobactins and Exochelins", Barclay et al., 1988.
Chemical Abstracts 98:157511, "Iron-Binding Compounds", Barclay et al., 1983.
Kirschner, Richard and Gary Fantini, "Role of Iron and Oxygen-Derived Free Radicals in Ischemia-Reperfusion Injury," Journal of The American College of Surgeons, vol. 179, No. 1, pp. 103-117, (Jul. 1994).
Scheibel and Stanton, "Antimalarial Activity of Selected Aromatic Chelators. IV. Cation Uptake by Plasmodium falciparum in the Presence of Oxines and Siderochromes," Molecular Pharmacology: An International Journal, vol. 30, No. 4, pp. 364-369, (Oct. 1986).
Sharman, Williams, Ewing and Ratledge, "Isolation, purification and structure of exochelin MS, the extracellular siderophore from Mycobacterium smegmatis," Biochemical Journal, pp. 187-196, (Jan. 1, 1995).
Barclay, Raymond and Colin Ratledge, "Iron-Binding Compounds of Mycobacterium avium, M. intracellulare, M. scrofulaceum, and Mycobactin-Dependent M. paratuberculosis and M. avium," Journal of Bacteriology, pp. 1138-1146, (Mar. 1983).
Barclay and Ratledge, "Metal Analogues of Mycobactin and Exochelin Fail to Act as Effective Antimycobacterial Agents," Zbl. Bakt. Hyg. A 262, 203-207 (1986).
Barclay and Ratledge, "Mycobactins and Exochelins of Mycobacterium tuberculosis, M. bovis, M. africanum and Other Related Species," Journal of General Microbiology, 134, 771-776 (1988).
Byler, Richard M. et al., "Hydrogen peroxide cytotoxicity in cultured cardiac myocytes is iron dependent," American Physiological Society, (1994).
Fiss, Ellen H. et al., "Identification of genes involved in the sequestration of iron in mycobacteria: the ferric exochelin biosynthetic and uptake pathways," Molecular Microbiology, 14(3), 557-569 (1994).
Gibson, Bradford W. et al. "Iron-Binding Exochelins" fromMycobacterium Tuberculosis: Structure, Characterization and Drug Design, In: Program of the Third International Symposium on Mass Spectrometry in the Health and Life Sciences (Sep. 13-18, 1994).
Hall, Richard Malcolm et al, "Exochelin-mediated Iron Uptake into Mycobacterium leprae," International Journal of Leprosy, vol. 51, No. 4, (1983).
Horwitz, Lawrence D. et al., "Marked Reduction in Myocardial Infarct Size Due to Prolonged Infusion of an Antioxidant During Reperfusion," Circulation 89:1792-1801, (Apr. 1994).
Kubica, George P. and Lawrence G. Wayne (Editors), The Mycobacteria: A Sourcebook, Published by Marcel Dekker, Inc., New York and Basel, Part A, pp. 606-627.
Lesnefsky, Edward J. et al., "Deferoxamine Pretreatment Reduces Canine Infarct Size and Oxidative Injury," The Journal of Pharmacology and Experimental Therapeutcs, vol. 253, No. 3, 1103-1109 (1990).
Macham, L.P. and Ratledge, "A New Group of Water-soluble Iron-binding Compounds from Mycobacteria: The Exochelins," Journal of General Microbiology, 89, 379-382 (1975).
Macham, Ratledge and Nocton, "Extracellular Iron Acquisition by Mycobacteria: Role of the Exochelins and Evidence Against the Participation of Mycobactin," Infection and Immunity, vol. 12, No. 6, pp. 1242-1251 (Dec. 1975).
Ratledge, C., "Iron metabolism in Mycobacterium," Iron Transport in Microbes, Plants and Animals, pp. 207 233 (1987).
Sritharan, M. and Colin Ratledge, "Co-ordinated expression of the components of iron transport (mycobactin, exochelin and envelope proteins) in Mycobacterium neoaurum," FEMS Microbiology Letters, 60 (1989) 183-186.
Stephenson, Maris C. and Colin Ratledge, "Specificity of Exochelins for Iron Transport in Three Species of Mycobacteria," Journal of General Microbiology, 116, 521-523 (1980).
Wheeler, PR and C Ratledge, "Metabolism in Mycobacterium leprae, M. tuberculosis and other pathogenic mycobacteria," British Medical Bulletin, vol.44, No. 3, pp. 547-561 (1988).
Gibson Bradford W.
Horwitz Lawrence D.
Horwitz Marcus A.
Reeve Joseph
Kleinberg Marvin H.
Krass Frederick
Lerner Marshall A.
Ram Michael J.
The Regents of the University of California
LandOfFree
Iron chelator and inhibitor of iron-mediated oxidant injury does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Iron chelator and inhibitor of iron-mediated oxidant injury, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Iron chelator and inhibitor of iron-mediated oxidant injury will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1875213